United Therapeutics Corporation is the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). The company's public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. The company's next-generation therapies are designed to address the unmet needs of patients living with conditions such as PAH, PH, and end-stage organ disease.